Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference GlobeNewswire - Thu May 21, 3:05PM CDT

BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage therapeutics company focused on developing transformative therapies targeting functional cures for immunological...

CUE : 21.90 (-3.28%)
Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments GlobeNewswire - Thu May 14, 3:07PM CDT

Enhanced the company’s portfolio with an exclusive license for, CUE-221, a Phase 2 program targeting allergic disease Hosted virtual R&D day showcasing CUE-401, a bifunctional IL-2 and TGF-B program...

CUE : 21.90 (-3.28%)
Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu May 7, 6:07PM CDT

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), today announced that, on May 3, 2026, the Company granted inducement equity awards to seven new employees, including its newly...

CUE : 21.90 (-3.28%)
Cue Biopharma Announces $30 Million Private Placement GlobeNewswire - Thu Apr 30, 3:25PM CDT

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate...

CUE : 21.90 (-3.28%)
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody GlobeNewswire - Thu Apr 30, 3:15PM CDT

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following...

CUE : 21.90 (-3.28%)
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company GlobeNewswire - Thu Apr 30, 3:05PM CDT

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 21.90 (-3.28%)
Cue Biopharma Announces 1-for-30 Reverse Stock Split GlobeNewswire - Wed Apr 22, 7:37AM CDT

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 21.90 (-3.28%)
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 GlobeNewswire - Wed Apr 15, 7:00AM CDT

BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 21.90 (-3.28%)
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement GlobeNewswire - Wed Apr 8, 7:00AM CDT

Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated...

CUE : 21.90 (-3.28%)
Cue Biopharma Announces CEO Transition GlobeNewswire - Fri Mar 27, 3:05PM CDT

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 21.90 (-3.28%)

Barchart Exclusives

Snowflake Stock Rallies on Blockbuster Q1 Results. It Turns Out That Gen AI Isn’t Eating Its Lunch. Barchart - 5 minutes ago
The posted numbers outpaced estimates while the company also raised guidance. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.